<- Go Home

Next Science Limited

Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.

Market Cap

AUD 28.3M

Volume

179.3K

Cash and Equivalents

AUD 971.2K

EBITDA

-AUD 8.2M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

AUD 18.2M

Profit Margin

82.48%

52 Week High

AUD 0.10

52 Week Low

AUD 0.04

Dividend

N/A

Price / Book Value

-50.74

Price / Earnings

-2.99

Price / Tangible Book Value

-21.31

Enterprise Value

AUD 32.6M

Enterprise Value / EBITDA

-4.08

Operating Income

-AUD 8.7M

Return on Equity

289.70%

Return on Assets

-50.99

Cash and Short Term Investments

AUD 971.2K

Debt

AUD 5.3M

Equity

-AUD 557.0K

Revenue

AUD 22.1M

Unlevered FCF

-AUD 3.1M

Sector

Health Care Equipment and Supplies

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches